Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort

Tomas Olsson1, Anat Achiron2, Lars Alfredsson3, Thomas Berger4, David Brassat5, Andrew Chan6, Giancarlo Comi7, Mefkure Eraksoy8, Harald Hegen4, Jan Hillert1, Poul Erik Hylgaard Jensen9, Lucia Moliola7, Kjell-Morten Myhr10, Annette Oturai9, Sven Schippling11,12, Aksel Siva13, Per Soelberg Sorensen9, Anne-Kathrin Trampe6, Thomas Weber14, James Potts15, Tatiana Plavina15, Dominic Paes15, Meena Subramanyam15, Heinz Wiendl16, Hussein Dib17, Deniz Üren17, Bernhard Hemmer18 and Dorothea Buck19

Abstract
JC virus (JCV) is an opportunistic virus known to cause progressive multifocal leukoencephalopathy. Anti-JC virus (Anti-JCV) antibody prevalence in a large, geographically diverse, multi-national multiple sclerosis (MS) cohort was compared in a cross-sectional study. Overall, anti-JCV antibody prevalence was 57.6%. Anti-JCV antibody prevalence in MS patients ranged from approximately 47% to 68% across these countries: Norway, 47.4%; Denmark, 52.6%; Israel, 56.6%; France, 57.6%; Italy, 58.3%; Sweden, 59.0%; Germany, 59.1%; Austria, 66.7% and Turkey, 67.7%. Prevalence increased with age (from 49.5% in patients < 30 years of age to 66.5% in patients ≥ 60 years of age; p < 0.0001 comparing all age categories), was lower in females than in males (55.8% versus 61.9%; p < 0.0001) and was not affected by prior immunosuppressant or natalizumab use.

Keywords
Multiple sclerosis, JC virus, natalizumab, STRATIFY-JCV, anti-JCV antibodies, epidemiology, infection risk, international study, antibody prevalence, immunosuppressant therapy, brain infection

Date received: 25th October 2012; accepted: 16th January 2013

Introduction
Progressive multifocal leukoencephalopathy (PML) is an infrequent opportunistic infection of the brain caused by the JC virus (JCV).1 Evidence of prior JCV exposure, via detectable anti-JCV antibodies, can be used to stratify natalizumab-treated multiple sclerosis (MS) patients at higher or lower risk for PML.2
**Table 1.** Patient demographics and prior MS treatments.a

<table>
<thead>
<tr>
<th></th>
<th>Overall (N = 10,280)</th>
<th>Austria (n = 666)</th>
<th>Denmark (n = 1,402)</th>
<th>France (n = 288)</th>
<th>Germany (n = 3,415)</th>
<th>Israel (n = 495)</th>
<th>Italy (n = 458)</th>
<th>Norway (n = 895)</th>
<th>Sweden (n = 2,497)</th>
<th>Turkey (n = 164)</th>
<th>p-valueb</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age (years)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean ± SD</td>
<td>39.4 ± 10.5</td>
<td>42.6 ± 12.3</td>
<td>42.5 ± 10.1</td>
<td>36.8 ± 10.1</td>
<td>39.0 ± 9.8</td>
<td>42.1 ± 10.8</td>
<td>35.9 ± 10.2</td>
<td>41.7 ± 10.0</td>
<td>37.5 ± 10.5</td>
<td>32.5 ± 8.7</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Median (range)</td>
<td>39.0 (12.0–80.0)</td>
<td>42.1 (17.7–79.8)</td>
<td>42.0 (15.0–80.0)</td>
<td>37.0 (16.0–66.0)</td>
<td>39.2 (16.2–73.5)</td>
<td>40.8 (18.1–78.8)</td>
<td>35.0 (12.0–69.0)</td>
<td>42.0 (12.0–71.0)</td>
<td>37.0 (12.0–75.0)</td>
<td>31.5 (17.0–53.0)</td>
<td></td>
</tr>
<tr>
<td>Sex, female (%)</td>
<td>71.6</td>
<td>71.2</td>
<td>69.8</td>
<td>71.5</td>
<td>73.1</td>
<td>71.3</td>
<td>66.8</td>
<td>69.7</td>
<td>71.9</td>
<td>75.9</td>
<td>0.0767</td>
</tr>
<tr>
<td><strong>Disease duration (years)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean ± SD</td>
<td>9.0 ± 6.9</td>
<td>9.0 ± 7.0</td>
<td>11.0 ± 7.2</td>
<td>8.9 ± 7.4</td>
<td>8.2 ± 6.3</td>
<td>11.1 ± 7.7</td>
<td>6.7 ± 5.0</td>
<td>ND</td>
<td>8.3 ± 7.0</td>
<td>7.3 ± 5.0</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Median (range)</td>
<td>7.7 (0–48.7)</td>
<td>7.4 (0–41.1)</td>
<td>10.0 (0–47.0)</td>
<td>7.0 (0–42.0)</td>
<td>7.0 (0–48.0)</td>
<td>9.6 (0–43.3)</td>
<td>6.1 (0.4–24.8)</td>
<td>ND</td>
<td>6.6 (0–48.7)</td>
<td>6.4 (0–24.3)</td>
<td></td>
</tr>
<tr>
<td>Immunosuppressant use (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prior natalizumab use (%)</td>
<td>48.9</td>
<td>8.1</td>
<td>49.4</td>
<td>0</td>
<td>68.5</td>
<td>0</td>
<td>98.0</td>
<td>37.9</td>
<td>45.3</td>
<td>37.7</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>

*aEstimates in each category (age, sex, disease duration, immunosuppressant use and natalizumab use) were based on information available for that country and the number of patients within that country.

b*p-values comparing all individual countries were obtained using one-way ANOVA for continuous variables and Pearson chi-square test for categorical variables.

The following immunosuppressant agents were used in each country: Austria: azathioprine, cyclophosphamide, methotrexate, mitoxantrone and mycophenolate; Denmark: methylprednisolone and mitoxantrone; France: unknown; Germany: azathioprine, cyclophosphamide, methotrexate and mitoxantrone; Israel: unknown; Italy: azathioprine, mitoxantrone, cyclophosphamide and daclizumab; Norway: unknown; Sweden: methylprednisolone and mitoxantrone; Turkey: azathioprine, cyclophosphamide and mitoxantrone.

ANOVA: analysis of variance; MS: multiple sclerosis; ND: no data available; SD: standard deviation.
It is useful to know the seroprevalence of anti-JCV antibodies in the population of interest and whether seropositivity varies in different geographic areas. We determined the prevalence of anti-JCV antibodies in MS patients in nine countries, and we examined the associations between seropositivity, demographic factors and prior therapies.

Figure 1. Prevalence of anti-JCV antibodies in (a) female and male patients, (b) patients with and without previous natalizumab use and (c) patients with and without immunosuppressant use overall, and by country. Patient numbers for each group are listed in the columns. There were no natalizumab-treated patients in Israel or France. *p < 0.04.

JCV: JC virus

(a) Anti-JCV antibody positive, % (95% CI)

(b) Anti-JCV antibody positive, % (95% CI)

(c) Anti-JCV antibody positive, % (95% CI)
Materials and methods

We collected demographic data and either serum or plasma samples from MS patients who were enrolled in approved studies around the world. Information about disease duration and prior immunosuppressant use was not available for Norway. All patients gave written informed consent when required. Samples were stored at −20°C to −80°C until analysis. Data were assembled by the investigators, and stored and analyzed by Biogen Idec and Elan Pharmaceuticals.

The primary endpoint was to define the prevalence of anti-JCV antibodies in each country. Associations between anti-JCV antibody seropositivity and demographic or disease characteristics were evaluated.

STRATIFY JCV™ (Focus Diagnostics, Cypress, CA) is a first-generation assay that was used to detect anti-JCV antibodies. Patient information was blinded during testing.

Summary statistics were used to analyze the anti-JCV antibody prevalence. An analysis of variance (ANOVA) or chi-square test was used to compare the baseline characteristics between countries. We used a chi-square test to assess the bivariate associations between demographic factors and anti-JCV antibody prevalence within individual countries. A logistic regression model, adjusted for age and sex, was used to compare anti-JCV antibody prevalence across countries.

Results

Table 1 shows patient numbers and demographics. The overall prevalence of anti-JCV antibodies in the pooled multinational cohort of 10,280 patients was 57.6% (95% confidence interval (CI), 56.6–58.6). Seroprevalence rates in individual countries were as follows: Norway, 47.4%; Denmark, 52.6%; Israel, 56.6%; France, 57.6%; Italy, 58.3%; Sweden, 59.0%; Germany, 59.1%; Austria, 66.7%; Turkey, 67.7%. The countries with the lowest (Norway and Denmark) and highest (Turkey) seroprevalence had significantly different seroprevalence from most or all other countries (data not shown).

Overall, the prevalence of anti-JCV antibodies tended to increase with age, and it differed significantly across age groups: < 30 years, 45.5%; 30–39 years, 54.8%; 40–49 years, 60.0%; 50–59 years, 67.6%; ≥ 60 years, 66.5% (p < 0.0001). In the majority of countries, females had a lower anti-JCV antibody prevalence than males, where the difference was statistically significant within the pooled group, overall (55.8% for females versus 61.9% for males; p < 0.0001) and in the Danish, Italian, Swedish and German patient populations (Figure 1(a)).

There was a trend toward lower anti-JCV antibody prevalence in patients exposed to natalizumab (56.7% seropositivity (95% CI, 55.3–58.1%) for exposed patients versus 58.3% seropositivity (95% CI, 56.9–59.6%) for unexposed patients overall; p = 0.1093; Figure 1(b)). After adjusting for age and gender, the association between anti-JCV antibody status and previous natalizumab exposure remained nonsignificant (p = 0.5698). No Israeli or French patients received natalizumab, and patient numbers were small (< 100) in some of the categories for the other countries, limiting a country-by-country analysis.

Immunosuppressant use data were available for 7324 patients in the pooled multinational cohort; 72.0% (5273 of 7324) did not receive immunosuppressant therapy. The prevalence of anti-JCV antibodies was not affected by immunosuppressant use in the overall population nor in the countries with data available, except in Israel, where anti-JCV seropositivity was more common among patients with prior immunosuppressant use (p = 0.0129) (Figure 1(c)). The association between prevalence of anti-JCV antibodies and immunosuppressant use remained nonsignificant, after adjusting for age and gender (p = 0.7981).

Discussion

This cross-sectional study found that 57.6% of MS patients in a multinational cohort had detectable anti-JCV antibodies. Except for Norway (47.4%), Austria (66.7%) and Turkey (67.7%), all of the countries had an anti-JCV antibody seroprevalence between 50% and 60%, consistent with other studies using STRATIFY JCV. As in previous reports, the prevalence of anti-JCV antibodies increased with age and it was significantly lower in females than in males. 0–8 Seropositivity was similar in male and female Israeli patients.

The risk of PML increases with the presence of anti-JCV antibodies, longer duration of natalizumab therapy (particularly > 2 years) and prior immunosuppressant use.2 We evaluated whether exposure to natalizumab or immunosuppressants had any effect on anti-JCV antibody prevalence. The small (2%) absolute difference in seroprevalence between natalizumab-treated and non-natalizumab-treated patients in this study is unlikely to be clinically significant, particularly because there were no available appropriately-matching samples from both before and after natalizumab treatment.

Overall and in most countries, we found there was no apparent difference in anti-JCV antibody prevalence between patients with and without immunosuppressant use, a result consistent with other studies. Only in Israel, anti-JCV antibody prevalence was significantly greater in patients with immunosuppressant use than in those without immunosuppressant use; however, the reason for this is unknown.

The limitations of this analysis included the small sample size for some countries (France and Turkey) compared with others (Denmark, Germany and Sweden); the unavailability of prior immunosuppressant information for Norwegian patients; the lack or limited number of natalizumab-treated patients in Israel, France and Austria and of non-natalizumab-treated patients in Italy; and the cross-sectional study design.
The risk of PML is low in patients who are negative for anti-JCV antibodies.\textsuperscript{2} In patients across all regions who are receiving or are considering initiating natalizumab therapy, their anti-JCV antibody status should be considered as part of a benefit-risk assessment.

**Acknowledgements**

Medical writing assistance was provided by Britt Anderson and editorial support was provided by Joshua Safran and Mary Kacillas of Infusion Communications. Their work was funded by Biogen Idec Inc. and Elan Pharmaceuticals Inc.

**Conflict of interest**

Tomas Olsson received honoraria for lectures from Biogen Idec, Genzyme/Sanofi, Novartis, Merck and Bayer and has received unrestricted MS research grants from the same companies. He has received research grants from the Swedish Research Council, the AFA Foundation, and the Knut and Alice Wallenberg Foundation.

Anat Achiron has nothing to disclose.

Lars Alfredsson received honoraria for lectures from Biogen Idec and research grants from the Swedish Research Council and the Swedish Council for Working Life and Social Research.

Thomas Berger has participated in meetings sponsored by and received honoraria (for lectures, advisory boards and consultations) from pharmaceutical companies marketing MS treatments. His institution received financial support through unrestricted research grants (from Allergan, Biogen Idec, Berlex, Bayer, CSL Behring, Merck Serono and Sanofi-aventis) and for participation in randomized controlled trials in MS, sponsored by Bayer Schering, Biogen Idec, Merck Serono, Novartis, Octapharma, Roche, Sanofi, Aventis and Teva.

David Brassat received honoraria for lecturing and travel expenses for attending meetings and advisory boards from Bayer Schering, Biogen Idec, Merck Serono, Novartis, Sanofi-aventis and Teva Neuroscience.

Andrew Chan has received personal compensation as a speaker or consultant for Allmirall, Bayer Schering, Biogen Idec, Merck Serono, Novartis, Sanofi-aventis and Teva Neuroscience. He has received research support from the German Ministry for Education and Research, Bayer Schering, Biogen Idec, Merck Serono and Novartis.

Giancarlo Comi received consulting fees for participating on advisory boards from Novartis, Teva, Sanofi-aventis, Genzyme, Merck Serono, Bayer and Actelion. He has also received lecture fees from Biogen, Novartis, Teva, Sanofi-aventis, Genzyme, Merck Serono and Bayer.

Mefkure Eraksoy has received honoraria for advisory boards and lectures/congress support from Biogen/Idec, Bayer HealthCare, Novartis, Merck and Teva.

Harald Hegen received honoraria for lectures from pharmaceutical companies marketing treatment for MS (Bayer Schering, Biogen Idec and Merck Serono).

Jan Hillert has received honoraria for serving on advisory boards for Biogen Idec and speaker’s fees from Biogen Idec, Merck Serono, Bayer-Schering, Teva and Sanofi-aventis. He has served as principal investigator for projects sponsored by, or has received unrestricted research support from, Biogen Idec, Merck Serono, Teva, Novartis and Bayer Schering. His MS research is funded by the Swedish Research Council.

Poul Erik Hyldgaard Jensen has nothing to disclose.

Lucia Moiola received lecture fees from Biogen Idec, Sanofi-aventis and Merck Serono.

Kjell-Morten Myhr received honoraria for lectures and participation in pharmaceutical company sponsored clinical trials and/or travel support from Bayer Schering, Biogen Idec, Novartis, Merck-Serono, Sanofi-aventis, Roche and GlaxoSmithKline.

Annette Oturai has served on scientific advisory boards for Novartis; has received speaker honoraria from Biogen Idec, Merck Serono, Sandoz and Novartis; and has received research support from the Danish MS Society, the Warwara Larsen Foundation and the Johnsen Foundation.

Sven Schippling received financial support for research activities from Bayer Schering, Biogen Idec and Merck Serono, and speaker or consulting fees from Bayer Schering, Biogen Idec, Merck Serono, Novartis, Sanofi-aventis and Teva.

Aksel Siva received honoraria for lectures, travel and registration coverage for attending several national or international congresses or symposia, plus his department received unrestricted research grants from Bayer Schering, Merck Serono, Biogen Idec, Novartis, Teva Aventis and Allergan.

Per Soelberg Sorensen served on scientific advisory boards for Biogen Idec, Merck Serono, Novartis, Genmab, Teva, Elan and GlaxoSmithKline; has been on steering committees or independent data monitoring boards in clinical trials sponsored by Merck Serono, Genmab, Teva, GlaxoSmithKline and Bayer Schering and has received funding of travel for these activities; has served as Editor-in-Chief of the European Journal of Neurology and is currently an editorial board member for Multiple Sclerosis Journal, European Journal of Neurology and Therapeutic Advances in Neurological Disorders; and has received speaker honoraria from Biogen Idec, Merck Serono, Teva, Bayer Schering, Sanofi-aventis, Genzyme and Novartis. His department received research support from Biogen Idec, Bayer Schering, Merck Serono, Teva, Baxter, Sanofi-aventis, BioMS, Novartis, Bayer, RoFAR, Roche, Genzyme, the Danish MS Society, the Danish Medical Research Council and the European Union Sixth Framework Programme: Life Sciences, Genomics and Biotechnology for Health.

Anne-Kathrin Trampe has nothing to disclose.

Thomas Weber, a member of the PML consortium, received honoraria from Bayer, Biogen Idec, GlaxoSmithKline, Merck Serono, Novartis, Sanofi and Teva. He received a research grant from Biogen Idec (held by the University of Hamburg Medical School).

James Potts, Tatiana Plavina, Dominic Paes and Meena Subramanyam are employees of Biogen Idec.

**Funding**

This work was supported by Biogen Idec Inc. and Elan Pharmaceuticals Inc.

**Authors’ note**

Portions of this work were presented at the 20th (2011) World Congress of Neurology, in Vancouver, Canada.

**References**


